Bimosiamose disodium  (Synonyms: TBC-1269Z)

Bimosiamose disodium (TBC-1269Z) is a nonoligosaccharide pan-selectin inhibitor with IC₅₀s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose disodium has anti-inflammatory effects^[1].

IC50: 88 μM (E-selectin), 20 μM (P-selectin), and 86 μM (L-selectin)^[1]

Bimosiamose (TBC-1269) operates by inhibiting neutrophil recruitment to the site of inflammation through blocking the initial rolling phase of recruitment. Bimosiamose (TBC-1269) inhibits cell recruitment and does not possess any cytotoxic effect on neutrophils^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment shows a significant increase in survival. Best overall survival, 70%, is observed when TBC-1269 is administered 15 minutes before reperfusion, and also shows a marked decrease in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration is also significantly ameliorated (81%). The histologic damage scores is also improved^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

906.88

C₄₆H₅₂Na₂O₁₆

187269-60-9

比莫西糖二钠盐

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Palma-Vargas JM, et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg. 1997 Oct;185(4):365-72.  [Content Brief]